Name | APTEKA N 392, OAO |
---|
INN | 6603022213 |
---|
KPP | 668301001 |
---|
OGRN | 1096603000075 |
---|
OKPO | 39925808 |
---|
FFSM | 33333-D |
---|
Address | 624272, Sverdlovskaya Oblast', g Asbest, ul Leningradskaya, d. D. 22 |
---|
Phone | 2-05-60 Contact details |
---|
Fax | +7 (343) 652-13-93 |
|
OKVED code | Type | Name of activity type |
---|
47.73 | Core activity | Retailing drugs in specialized stores (pharmacies) | 47.29 | Additional activity | Retail trade of other food products in specialized stores | 47.7 | Additional activity | Retail sale of other goods in specialised stores | All types of activities | 47.74 | Additional activity | Retailing products used for medical purposes, orthopedic goods in specialized stores | 47.75 | Additional activity | Retailing of cosmetics and personal hygiene products in specialized stores |
Registration date | 22.01.2009 |
---|
Registering department | Inspektsiya Federal'noy nalogovoy sluzhby po g.Asbestu Sverdlovskoy oblasti |
---|
|
APTEKA N 392, OAO (Sverdlovsk Oblast; INN 6603022213) was registered on 22 Jan 2009. The company's authorized capital as of July 1, 2012 was 2606000 rub. Type of ownership of APTEKA N 392, OAO - Open joint-stock companies. Form of ownership of APTEKA N 392, OAO - Municipal property. Principal activities of APTEKA N 392, OAO: retailing drugs in specialized stores (pharmacies) (47.73), retail trade of other food products in specialized stores (47.29), retail sale of other goods in specialised stores (47.7). |
Economic indicators2023
Net loss (RA) of APTEKA N 392, OAO made up 226.00 thousand RUB over 2023 compared to net profit of 76.00 thousand RUB over 2022, the company informed. Revenue decreased in the accounting period by 2.11% to 39.13 million RUB from 39.97 million RUB in 2022; cost of goods sold grew by 4.52% to 28.33 million RUB from 27.11 million RUB; sales profit fell by 28.55% to 508.00 thousand RUB from 711.00 thousand RUB. 2022
Net profit (RAS) of APTEKA N 392, OAO grew over 2022 by 10.29% to 75.00 thousand RUB from 68.00 thousand RUB over 2021, the company informed. Revenue increased in the accounting period by 6.83% to 39.97 million RUB from 37.41 million RUB over 2021; cost of goods sold grew by 9.22% to 27.11 million RUB from 24.82 million RUB; sales profit fell by 13.50% to 711.00 thousand RUB from 822.00 thousand RUB. 2021
Net profit (RAS) of APTEKA N 392, OAO grew over 2021 by 6.25% to 68.00 thousand RUB from 64.00 thousand RUB over 2020, the company informed. Revenue increased in the accounting period by 2.77% to 37.41 million RUB from 36.41 million RUB over 2020; cost of goods sold grew by 1.85% to 24.82 million RUB from 24.37 million RUB; sales profit went up by 5.79% to 822.00 thousand RUB from 777.00 thousand RUB. 2020
Net profit (RAS) of APTEKA N 392, OAO dropped in 2020 by 14.67% to 64.00 thousand RUB from 75.00 thousand RUB over the same period in 2019, the company informed. Revenue decreased in the accounting period by 8.18% to 36.41 million RUB from 39.65 million RUB in 2019; cost of goods sold decreased by 9.69% to 24.37 million RUB from 26.98 million RUB; sales profit went up by 2.24% to 777.00 thousand RUB from 760.00 thousand RUB. 2019
Net profit (RAS) of APTEKA N 392, OAO dropped in 2019 by 38.52% to 75.00 thousand RUB from 122.00 thousand RUB over the same period in 2018, the company informed. Revenue increased in the accounting period by 2.87% to 39.65 million RUB from 38.54 million RUB over 2018; cost of goods sold grew by 3.93% to 26.98 million RUB from 25.96 million RUB; sales profit went up by 4.40% to 760.00 thousand RUB from 728.00 thousand RUB. 2018
Net profit (RAS) of APTEKA N 392, OAO grew over 2018 1.58 times to 122.00 thousand RUB from 77.00 thousand RUB over 2017, the company informed. Revenue increased in the accounting period by 7.15% to 38.54 million RUB from 35.97 million RUB over 2017; cost of goods sold grew by 8.23% to 25.96 million RUB from 23.99 million RUB; sales profit went up by 16.11% to 728.00 thousand RUB from 627.00 thousand RUB. 2017
Net profit (RAS) of APTEKA N 392, OAO grew over 2017 by 18.46% to 77.00 thousand RUB from 65.00 thousand RUB over 2016, the company informed. Revenue increased in the accounting period by 1.12% to 35.97 million RUB from 35.57 million RUB over 2016; cost of goods sold remained at the same level amounting to 23.99 million RUB compared to 23.99 million RUB; sales profit went up 1.69 times to 627.00 thousand RUB from 370.00 thousand RUB. 2016
Net profit (RAS) of APTEKA N 392, OAO grew over 2016 by 20.37% to 65.00 thousand RUB from 54.00 thousand RUB over 2015, the company informed. Revenue increased in the accounting period by 2.31% to 35.57 million RUB from 34.77 million RUB over 2015; cost of goods sold decreased by 0.74% to 23.99 million RUB from 24.17 million RUB; sales profit went up by 25.00% to 370.00 thousand RUB from 296.00 thousand RUB. 2014
Net profit (RAS) of Apteka N 392, OAO over 2014 was the same as in 2013 reaching 46.00 thousand RUB, the company informed. Revenue increased in the accounting period by 2.10% to 33.94 million RUB from 33.24 million RUB over 2013; cost of goods sold grew by 5.99% to 24.33 million RUB from 22.95 million RUB; sales profit fell by 10.38% to 259.00 thousand RUB from 289.00 thousand RUB. 2013
Net profit (RAS) of Apteka N 392, OAO dropped in 2013 2.65 times to 46.00 thousand RUB from 122.00 thousand RUB over the same period in 2012, the company informed. Revenue increased in the accounting period by 8.44% to 33.24 million RUB from 30.66 million RUB over 2012; cost of goods sold grew by 7.54% to 22.95 million RUB from 21.34 million RUB; sales profit fell by 39.67% to 289.00 thousand RUB from 479.00 thousand RUB. 2012
Net profit (RAS) of Apteka N 392, OAO dropped in 2012 3.03 times to 122.00 thousand RUB from 370.00 thousand RUB over the same period in 2011, the company informed. Cost of goods sold grew by 20.18% to 21.34 million RUB from 17.76 million RUB; sales profit fell by 31.86% to 479.00 thousand RUB from 703.00 thousand RUB.
unlimited access to database "Kontragent" download any information within 24 hours
Companies in the region
|